Almirall-backed psoriasis support app Claro launches in Europe
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to […]
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to […]
BARCELONA, Spain, a global biopharmaceutical company focused on skin health, and IRB Barcelona (the Institute for Research in Biomedicine), an independent, international research centre engaged in […]
Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona […]
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks […]
Spanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its core area of expertise. The latest edition […]
Shots: Kaken to receive an up front in cash and is eligible to receive milestones and royalties on the sales of the product. Almirall plans […]
Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this […]
It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body […]
Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies Sarepta […]
Shots: Tyris to receive up front, research milestone along with research funding and will be responsible for generating clinical lead candidates and will further progress […]
Finnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken their psoriasis medicine and sends them a […]
Finnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken their psoriasis medicine and sends them a […]
Novartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Buried deep in the Swiss company’s Q2 […]
Copyright © 2024 | WordPress Theme by MH Themes